View Older Stories View More Recent Stories

Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 14, 2016 01:15AM Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jun 9, 2016 09:00AM Novelis Appoints Devinder Ahuja as Senior Vice President, Chief Financial Officer
May 25, 2016 09:23AM Novartis (NVS) Updates on Outlook into 'Meet Management' Event
May 25, 2016 05:43AM Novartis willing to sell Roche stake without demanding premium - CEO
May 25, 2016 01:00AM Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event
May 23, 2016 12:16PM Novartis executive exodus complicates drugmaker's rebuilding job
May 17, 2016 12:04PM Novartis splits drugs business into two, pharma chief to leave
May 17, 2016 11:35AM Novartis (NVS) Splits Pharmaceuticals Division into Two Divisions; Announces Management Changes
May 17, 2016 11:30AM Novartis focuses Pharmaceuticals Division by creating two business units, Novartis Pharmaceuticals and Novartis Oncology; appoints leaders to the Executive Committee of Novartis
May 17, 2016 10:30AM uStudio Named a “Hot Vendor” and Innovator in Enterprise Video
May 13, 2016 01:30AM ThromboGenics Business Update - Q1 2016
May 12, 2016 12:00PM EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial
Apr 27, 2016 02:00AM New Ocriplasmin Research Findings Presented
Apr 21, 2016 06:53AM Novartis (NVS) Misses Q1 EPS by 2c
Apr 21, 2016 01:01AM Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth
Apr 19, 2016 07:00PM Allergies and your eyes: What you need to know this spring by Brandpoint
Apr 12, 2016 11:00AM uStudio Founder Joins CTA Internet Video Initiative
Mar 31, 2016 01:00AM Novartis publishes updated 2015 segment financials reflecting new division structure
Mar 22, 2016 02:22PM Fitch Affirms Ratings of Novartis (NVS) Following Recent Review; Outlook Stable
Mar 10, 2016 09:00AM VisionCare Ophthalmic Technologies Announces Appointment of Industry Veteran, Thierry Clidiere, to its Board of Directors
Mar 1, 2016 02:23AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Mar 1, 2016 02:00AM ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London
Feb 18, 2016 01:00AM Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc.
Feb 11, 2016 01:59AM Publicis Groupe: 2015 Annual Results
Feb 1, 2016 10:48AM Leading Corporations Find EXHIBITORLIVE a Strategic Marketing Weapon as Attendance and Exhibition Increases
Jan 27, 2016 08:41AM Novartis (NVS) Misses Q4 EPS by 4c; Announces FY16 Strategy, Management Changes
Jan 27, 2016 01:00AM Novartis delivered strong sales growth and core margin expansion (cc[1]) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations
Jan 22, 2016 10:00AM Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration
Jan 14, 2016 08:00AM Novartis (NVS) Named Top Global Pharma Pick at Jefferies
Jan 13, 2016 01:35AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial
Jan 13, 2016 01:30AM ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retino
Jan 11, 2016 07:00AM Ocular TherapeutixTM Strengthens Executive Management Team with the Appointment of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., as Chief Medical Officer
Nov 18, 2015 11:50AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA(r) (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 18, 2015 11:40AM ThromboGenics Reports Positive 2 Year Results from the OASIS Study with JETREA® (ocriplasmin) for the treatment of Symptomatic VMA/VMT and Macular Hole
Nov 15, 2015 12:00PM Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting
Nov 13, 2015 01:37AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 13, 2015 01:30AM ThromboGenics Presents Full OASIS JETREA Trial Data Analysis (incl ERG) and Further Real World Clinical Data at Upcoming AAO 2015 in Las Vegas
Nov 12, 2015 01:35AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA(r) for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 12, 2015 01:30AM ThromboGenics Announces FDA Acceptance of Investigational New Drug (IND) Application for Phase II Study with JETREA® for the Treatment of Non-Proliferative Diabetic Retinopathy (CIRCLE)
Nov 5, 2015 11:50AM ThromboGenics Business Update - Q3 2015
Nov 5, 2015 11:40AM ThromboGenics Business Update - Q3 2015
Oct 27, 2015 06:16AM Novartis (NVS) Misses Q3 EPS by 4c
Oct 27, 2015 02:00AM Novartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidance
Oct 21, 2015 08:00AM Allegro Ophthalmics Names Scott Cooper as Chief Financial Officer and Vice President of Business Development and Mohamed Genead, MD, as Executive Medical Director
View More Recent Stories View Older Stories